Jinlixi (Xeligekimab Injection) – Atopic Dermatitis | HongKong DengYue Medicine

Xeligekimab Injection Application Scope

Xeligekimab Injection is indicated for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy. It works by selectively targeting interleukin-4 receptor alpha (IL-4Rα), thereby modulating the overactive Th2 immune response that drives inflammation and skin lesions in atopic dermatitis. This therapy helps to reduce itching, redness, and skin thickening, improving overall skin condition and quality of life for patients suffering from chronic, persistent eczema that is not adequately controlled with topical treatments.

Xeligekimab Injection Characteristics

• Ingredients: Xeligekimab

• Properties:​ Human monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα)

• Packaging Specification:​ 100 mg/1 mL per vial × 1 vial/box

• Storage:​ Store at 2–8°C; protect from light; do not freeze

• Expiry Date: As indicated on packaging (typically 24 months from manufacturing date)

• Executive Standard: ​In accordance with the pharmacopoeia and regulatory requirements

• Approval Number: As per the national drug regulatory authority

• Date of Revision: Latest update per product labeling

• Manufacturer: As per product packaging

Guidelines for the Use of Jinlixi

• Dosage and Administration:

  • Recommended Dose: Initial dose: 400 mg, followed by 200 mg every 2 weeks (typical regimen for adults)

  • Administration: Subcutaneous injection

  • Missed Dose:​ Administer as soon as possible; continue with original schedule

• Adverse Reactions:

  • Common Adverse Reactions: Injection site reactions, headache, nasopharyngitis, upper respiratory tract infection

  • Serious Adverse Reactions: Hypersensitivity reactions, severe infections, eosinophilia, conjunctivitis

    ​

• Contraindications:

  • Known hypersensitivity to xeligekimab or excipients

  • Active serious infections

• Precautions:

  • Monitor for signs of infection during therapy.

  • Use with caution in patients with immune system disorders.

  • Avoid live vaccines during treatment.

Xeligekimab Injection Interactions

• Limited interaction data available

• Avoid co-administration with live vaccines

• No known significant interactions with common medications

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
•  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.